Genomic ALK alterations in primary and relapsed neuroblastoma.
Carolina RosswogJana FassunkeAngela ErnstBirgid Schömig-MarkiefkaSabine Merkelbach-BruseChristoph BartenhagenMaria CartolanoSandra AckermannJessica TheissenMirjam Blattner-JohnsonBarbara JonesKathrin SchrammJanine AltmüllerPeter NürnbergMonika OrtmannFrank BertholdMartin PeiferReinhard ButtnerFrank WestermannJohannes Hubertus SchulteThorsten SimonBarbara HeroMatthias FischerPublished in: British journal of cancer (2023)
The considerably increased frequency of ALK mutations at relapse and their high prevalence in young stage 4 patients suggest surveying the genomic ALK status regularly in these patient cohorts, and to evaluate ALK-targeted treatment also in intermediate-risk patients.